



EUROPEAN COMMISSION
HEALTH & CONSUMERS DIRECTORATE-GENERAL
Public Health and Risk Assessment
Risk assessment

Scientific Committee on Consumer Safety

9th meeting of the WG 'Cosmetic Ingredients' – 9 March 2010

Minutes

1. WELCOME AND APOLOGIES

The Chair of the working group (WG) welcomed the participants and communicated the apologies received.

2. ADOPTION OF THE AGENDA

The draft agenda was adopted (annex 1).

3. DECLARATION OF INTEREST ON MATTERS OF THE AGENDA

No member declared any interest that could prevent him/her from participating in the discussion of the items on the agenda.

4. DRAFT OPINIONS

Draft opinions on the following substances were discussed by the Working Group:

- 4.1. Cyclomethicone (D4/D5)
- 4.2. Vitamin K1
- 4.3. Erythrosine
- 4.4. Melatonin
- 4.5. CMR borates, perborates
- 4.6. DEGEE

The draft opinions on Cyclomethicone (D4/D5), Erythrosine and on Vitamin K1 were addressed to the plenary meeting of 23 March for adoption.

5. PROGRESS REPORTS

The members of the WG were updated on the progress of the following mandates:

- 5.1. P81, Zinc pyrithione
- 5.2. S74, Polysilicone-15
- 5.3. P95, Ethyl Lauroyl Arginate
- 5.4. P32, Triclosan, toxicology
- 5.5. DHA
- 5.6. P63, Quaternium-15
- 5.7. P82, Parabens

6. NEW REQUESTS

- 6.1. Arbutin / desoxyarbutin

Arbutin and deoxyarbutin are intended to be used as a skin lightening ingredient in cosmetic preparations up to a maximum concentration of respectively 7.0% and 3.0% in leave-on products.

7. COMMENTS ON OPINIONS ADOPTED ON 8 DECEMBER 2009

Comments were received on the following opinions adopted in the SCCS plenary of 8 December 2009:

- 7.1. P56, MCI/MI
- 7.2. P72, Alkyl (C₁₆, C₁₈, C₂₂) trimethylammonium, bromide and Chloride

The comments were discussed and the opinions were adapted according to the outcome of the discussion.

8. ANY OTHER BUSINESS

No specific items were raised.

The next meeting will take place on 27 April 2010.

Annex 1: draft agenda

Annex 1

**Scientific Committee on Consumer Safety (SCCS)
WG on Cosmetic Ingredients****9 March 2010****DRAFT AGENDA**

- 1. Welcome and apologies**
- 2. Adoption of the agenda**
- 3. Declaration of interest on matters on the agenda**
- 4. Draft opinions on:**
 - 4.1. Cyclomethicone (D4)
 - 4.2. Vitamin K1
 - 4.3. Erythrosine
 - 4.4. Melatonin
 - 4.5. CMR borates, perborates
 - 4.6. DEGEE
- 5. Progress reports**
 - 5.1. P81, Zinc pyrithione
 - 5.2. S74, Polysilicone-15
 - 5.3. P95, Ethyl Lauroyl Arginate
 - 5.4. P32, Triclosan
 - 5.5. DHA
 - 5.6. P63, Quaternium-15
 - 5.7. P82, Parabens
- 6. New requests**
 - 6.1. Arbutin / desoxyarbutin
- 7. Comments on opinions adopted on 8 December 2009**
 - 7.1. P56, MCI/MI
 - 7.2. P72, Alkyl (C₁₆, C₁₈, C₂₂) trimethylammonium, bromide and Chloride
- 8. Any Other Business**